Enzon Inc. regulatory update

ENZN received three U.S. patents covering its Single-Chain Antigen-Binding (SCA) protein technology. SCA is used to deliver therapeutic agents to targeted disease sites. Patent No. 5,534,621 covers immunopurification methods; Patent No. 5,518,889 covers immunoassay methods; and Patent No. 5,455,030 covers immunotherapeutic methods. ...